Vivus Obesity Drug Market Is Very Large, Tam Says

July 18 (Bloomberg) -- Peter Tam, president of Vivus Inc., talks about the U.S. Food and Drug Administration's approval of the company's obesity drug Qsymia. He speaks with Adam Johnson on Bloomberg Television's "Street Smart." Barry Ritholtz, chief executive officer of FusionIQ, also speaks. (Source: Bloomberg)